GOSS vs. SYRS, CNTX, SGMT, INCR, CYBN, CTMX, RPTX, RAPT, RIGL, and IMAB
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Syros Pharmaceuticals (SYRS), Context Therapeutics (CNTX), Sagimet Biosciences (SGMT), InterCure (INCR), Cybin (CYBN), CytomX Therapeutics (CTMX), Repare Therapeutics (RPTX), RAPT Therapeutics (RAPT), Rigel Pharmaceuticals (RIGL), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking.
Syros Pharmaceuticals received 216 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 65.32% of users gave Gossamer Bio an outperform vote while only 63.89% of users gave Syros Pharmaceuticals an outperform vote.
Gossamer Bio currently has a consensus price target of $7.65, suggesting a potential upside of 1,186.80%. Syros Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 180.00%. Given Gossamer Bio's higher probable upside, research analysts clearly believe Gossamer Bio is more favorable than Syros Pharmaceuticals.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Gossamer Bio has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Syros Pharmaceuticals' average media sentiment score of 1.84 beat Gossamer Bio's score of 1.23 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.
Syros Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of -395.36% beat Gossamer Bio's return on equity.
Summary
Gossamer Bio and Syros Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
